Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BNVI .0145 up 418% if anyone is still around
You hit the that nail right on the head. Something is amiss on our board. The board is like an incestuous old family; everyone knows something is wrong but nobody knows how to fix it.
Seems to be a shorter's paradise.
Most people who post are not traders of any sort; mostly people who are highly intelligent and have invested in the company because they understand the science.
Like I said before, in 90 days or less it won't matter.
Things just changed again. I am absolutely at a loss. I just checked and Mr. LeGiOn is no longer listed as a moderator on the board. Maybe our complaints had him removed. I did notice that there are a few new moderators on the board. I think he is still there, just with a new alias.
I don't know but for me run coming soon...
I'm with ya, bro. They've got a
last second offer, or sumthin?
I'm the only one here. I talk to myself...HAHA
I bought BNVIQ six months ago and I followed him.
Chapter 7 but something cooking here...
BNVIQ
For me: YES $$$$$$ here....Go BNVIQ
BNVIQ is getting attension and momentum
Since Bionovo filed for Chapter 7, what is next? Are they dead? What about their products in clinical trials? Anyone know what's going on here? Will they emerge under a different name? Did they basically turn out the lights at corporate and dissolve?
Up 290% over the last month....39.29% over the last 3 days
i don't know why there is any question about value, name change, etc. bnvi declared bankruptcy. they will not re-organize, but somebody should keep track of the ownership of Menerba although it looks like a failed compound.
i don't trust issack and stupid mary.
Provided is a link to access for your answer,the latest news about the otc market and pink sheets market, otc are know as volatile stocks !!
http://www.otcbb.com/asp/Info_Center.asp
On a clear day you can see forever, which is it?
As well that it is transparent Prowler1 !!
WallllStreetMyWay.......... since you tend to post as to information that the companies stock will explode and there is a name change on the way, would you dare try your hand at posting, that the new name change will carry the Current Stock OR will it be a New Name with a New Stock issue?
A name change carrying the current o/s of 80mil+ and a news release of another source or whatever, may dance a little for the play you seem to support, other then, it's bnvi final last farewell good-bye forever along with their great show of a bkcy.
VBR
Slojab then the only advice I can offer is give the company time !
As I currently seen the name change recent activity.
Do you have a timeline for this?
It's in bankruptcy, you know.
http://www.sec.gov/investor/pubs/bankrupt.htm
If you like what your seeing just wait til you see how high BNVIQ explodes,name change we will see? I don't miss out on the dips Bnviq if so is dirt cheap right nows ?!!
yea atdf hold that .065 here come after 2 cant wait
the PIII trials have all been canceled. No information posted since june 2011
http://clinicaltrials.gov/ct2/show/NCT01300078?term=menerba&rank=1
You truly might be the last one out to turn off the lights.
Bionovo is still in ph3 trials for Menerba. I'm wondering- even though they are in ch7 bankruptcy, if they have a successful ph3 trial then won't there still be some type of value to the company?
I haven't had time to really dig deep and see if there were other examples of biotech's on the bring of extinction that were brought back into play by one last drug trial.
I own a lot shares of this company - I mean a lot. Wondering if anyone has any real news - not hype.
Old News with possibilities', PIPE investments, filed SEC Form SC 13G indicating that it holds 4.23 million or 9.9% of outstanding shares, and also warrants to purchase an additional 6.78 million shares.
Quantum Fuel System Tech (QTWW) and Bionovo Inc. (BNVI):
Also, Empery filed a SEC Form SC 13G on Monday indicating that it holds 4.91 million shares or 9.9% of outstanding shares, and warrants to purchase an additional 5.74 million shares of BNVI, a clinical-stage drug discovery and development company that focuses on developing drug candidates in the areas of women's health and cancer. Besides Empery, New York-based multi-strategy hedge fund Hudson Capital Management also filed SEC Form SC 13G today indicating that it holds 4.50 million shares, and warrants to purchase an additional 5.74 million shares.
"Bionovo is currently recruiting patients to its Phase 3 pivotal trial for Menerba and trial results are expected to be released in Q1, 2013.
Form 8-K for BIONOVO INC
--------------------------------------------------------------------------------
1-Nov-2012
Bankruptcy or Receivership
Bionovo received a response to a formal dispute appeal with the FDA, stating that MF101 is approvable if safety and efficacy were to be demonstrated in clinical testing. More so, the FDA stated clearly and unambiguously that the CMC package and the 10 batch records for MF101, Bionovo provided for the Phase 3 clinical testing were accepted by the Agency."
BIONOVO INC FinancialsEDGAR Online Financials (Wed, Feb 13)
[ihttp://finance.yahoo.com/q/is?s=bnviq]
Bionovo
Organization.... Bionovo (NASDAQ: BNVI) is an American biotechnology company focused on the discovery and development of botanically derived treatments for women's health and cancer based in Emeryville, California. The company currently has two drug candidates in U.S. Food and Drug Administration (FDA) clinical trials- Menerba (formerly known as MF101) a selective estrogen receptor beta agonist for hot flashes associated with menopause and Bezielle (formerly BZL101) for advanced breast cancer.
Discovery and development platform
Bionovo uses traditional Chinese medicine (TCM) as its discovery engine, isolating, purifying and testing potent active ingredients from herbs and other botanicals, then formulating them into products which can be packaged as powders or pills for easy use by patients.
The company has identified the active chemical components underpinning the mechanism of action for all of their lead drug candidates, and in some cases, has developed synthetic methods of production. They are developing their drugs in accordance with the U.S. FDA's botanical drug guidelines.
Drug pipeline
Bionovo's drug pipeline currently has two drug candidates in clinical trials and several additional candidates positioned to enter clinical trials upon the receipt of funding or partnership.
Menerba
Bionovo’s lead drug candidate, Menerba (formerly known as MF101), is a novel selective estrogen receptor beta (ERß) agonist designed to treat vasomotor symptoms (hot flashes) associated with menopause.
Although Menerba is a selective estrogen receptor modulator (SERM), it is distinct from the other FDA-approved SERMs, such as tamoxifen and raloxifene, since these drugs have mixed agonist/antagonist activity and are not selective in transcriptional regulation to one of the two known estrogen receptor subtypes.
Menerba completed its Phase II clinical trial, showing the drug to be safe, clinically efficacious and well tolerated. The drug will begin its Phase III clinical trial pending FDA approval.
Bezielle
Bezielle (also called BZL101) is an oral drug designed for the treatment of advanced breast cancer. The drug is derived from the herb, Scutellaria Barbata, which is used in traditional Chinese medicine to treat cancer. Bezielle is selectively cytotoxic to most of twelve breast cancer cell lines examined as well as to a number of cancer cell lines of different tissue origins such as prostate, lung, colon, ovarian and pancreatic cancers. At the same dose, Bezielle does not induce appreciable cell death in normal cells such as fibroblasts and normal mammary epithelial cells and lines.
Bezielle’s mechanism of action targets diseased cells while leaving normal cells healthy and intact by inhibiting glycolysis production. Normal cells depend primarily on the citric acid cycle (>85%) and very little on glycolysis (<7%) for energy production. In contrast, cancer cells depend largely on glycolysis (>85%) for energy production. Bezielle induces strong oxidative stress in cancer cells leading to severe DNA damage
, but in normal cells the effect is blunted due to their different metabolic profile. Cancer cells attempt but ultimately fail to repair DNA damage that results in the inhibition of glycolysis and cancer cell death while normal cells remain unharmed. Bezielle has completed Phase 1A and 1B clinical trials for advanced metastatic breast cancer.
Early stage drug candidates
Seala (also known as VG101) for vaginal atrophy has been approved by the FDA to begin a Phase I/II clinical trial upon receipt of funding.
BN107 and BN108, both designed to treat advanced breast cancer, are slated to begin Phase I/II clinical trials upon funding.
Bezielle is scheduled to begin a Phase I/II clinical trial for the treatment of pancreatic cancer upon funding.
Bionovo Makes $5 Million Stock Sale Deal
San Francisco Business Times, January 2012!!
http://bionovo.com/investors/news
BioNovo, Inc (BNVIQ)
I agree BioNovo, Inc (BNVIQ) will now follow through on everything they have said they will do in bankruptcy or reversal, Facts are there speaking and i cant wait and watch for a potentially this officialism of news to take !
Well see the trying of this is a strong recommendation,id stay in early here and waiting for get a news of a reversal!!!
I believe its a penny play with bankruptcy details and will go way up with a tiny float!!!
Its a CHAPTER 7
It's going to be de-registered.
Skull and crossbones stuff.
Liabilities here ensure they're going to bury it deep.
BNVI changed to BNVIQ:
http://www.otcbb.com/asp/dailylist_detail.asp?d=02/07/2013&mkt_ctg=NON-OTCBB
BIONOVO INC Filed by: Hudson Bay Capital Management LP
2:07 PM ET, 02/06/2013 - Morningstar, Inc.
02/06/2013 N/A SC 13G/A Amended Statement of Ownership yes
As 'BioNovo, Inc ($BNVIQ)' still news good be a huge future play coming!!, Well see the trying of this is a strong recommendation,id stay in early here and waiting for get a news of a reversal!!!
I believe its a penny play with bankruptcy details and will go way up with a tiny float!!!
A BioNovo, Inc now may be a great time to establish a position in. $BNVIQ is looking pretty good!!!
Trying to remember the last time I saw a Q stock where the financiers were forced by the bankruptcy court (?) to file amended forms 13 to "correct" prior filing information, including having them claiming, in the most recent amendments, to own VASTLY LESS in interest than their prior filings had claimed... while also correcting them to reflect they are in fact "control persons" ?
The change doesn't appear to be pointing toward any source of potential value...
Instead, it's pointing out responsibility ?
The company filed in October, saying "All of the Company's assets will be liquidated. The Company estimates that, after any exempt property is excluded and administrative expenses paid, there will be no funds available for distribution to unsecured creditors."
http://www.sec.gov/Archives/edgar/data/1203957/000114420412058973/v327205_8k.htm
Curious if you've ever seen a BK stock that took THAT long to reflect a changed trading symbol ? Someone asleep at the switch ?
BNVI changed to BNVIQ:
http://www.otcbb.com/asp/dailylist_detail.asp?d=02/07/2013&mkt_ctg=NON-OTCBB
As 'BioNovo, Inc (BNVI)' still news good be a huge future play coming!!, Well see the trying of this is a strong recommendation,id in ealry here and waiting for get a news of a reversal!!!
I believe its a penny play with bankruptcy details and will go way up with a tiny float!!!
BNVI Security Details
Share Structure
Market Value1 $642,611 a/o Feb 06, 2013
Shares Outstanding 80,326,361 a/o May 01, 2012
Float Not Available
Authorized Shares Not Available
Par Value 0.001
Shareholders
Shareholders of Record 81 a/o Mar 30, 2012
Security Notes
Note = Company delisted from NASDAQ on 02/07/12
Capital Change=shs decreased by 1 for 5 split. Pay date=08/31/2010.
Short Selling Data
Short Interest 2,571 (-73.1%)
Jan 15, 2013
Significant Failures to Deliver No
BioNovo, Inc (BNVI) Id rather let"s, get the scoop, always on the cutting edge of breaking news we need to hear from the company.
BioNovo, Inc
BIONOVO INC Filed by: Hudson Bay Capital Management LP
2:07 PM ET, 02/06/2013 - Morningstar, Inc.
02/06/2013 N/A SC 13G/A Amended Statement of Ownership yes
'BioNovo, Inc (BNVI)'
Well i am glad i am not with the heard ,As 'BioNovo, Inc (BNVI)' still news good be a huge future play coming!!, Well see the trying of this is a strong recommendation,id in ealry here and waiting for get a news of a reversal!!!
I believe its a penny play with bankruptcy details and will go way up with a tiny float!!!
That's easy...
Quit waiting for it.
It's never gonna happen.
This thing is dead.
And it's gonna stay dead.
Until the SEC de-registers it.
There is no "shell" play here.
Too many liabilities.
So, anything that "happens" here... is a scam ? Not sure why anyone would find that confusing ?
$Id like much more than every day watch for the News...!!!
Followers
|
52
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1708
|
Created
|
01/22/07
|
Type
|
Free
|
Moderators |
http://www.bionovo.com/
http://finance.yahoo.com/q/ks?s=BNVI
Bionovo, Inc., a development stage company, engages in the discovery and development of drugs in the areas of cancer and women?s health primarily in the United States. It develops drugs to treat breast and ovarian cancers, and for menopause. The company?s product and drug pipeline includes MF101, a selective estrogen receptor beta agonist, which is designed to alleviate the symptoms of menopause, including hot flashes, night sweats, and bone mineral loss; and BZL101, an apoptosis inducing factor translocator/activator, which is used as an anticancer agent for breast and ovarian cancers, as well as used for the treatment of other solid tumors. In addition, its drug pipeline, which is not entered human clinical trials includes AA102, an apoptosis inducer, which is used as an anticancer agent that attenuates mitochodrial membrane potential to cause a cytochrome c release and caspase activation to induce apoptosis; and VG101, vasodilator and an antimicrobial agent, which is an intra-vaginal gel for the treatment of postmenopausal vaginal dryness. The company has collaboration with the University of California at San Francisco; University of California at Berkeley; University of California at Davis; University of Texas, Southwestern; and University of Colorado Health Sciences College. Bionovo was founded in 2002 and is headquartered in Emeryville, California.
http://www.dawsonjames.com/portal/BNVI_Initiation_11_3_2009.pdf
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |